{
    "2019-04-15": [
        [
            {
                "time": "",
                "original_text": "建议关注医药国改机会，港股医药配置价值凸显｜【光大医药·周报】",
                "features": {
                    "keywords": [
                        "医药",
                        "国改",
                        "港股",
                        "配置价值"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "汇丰：升上海医药(02607.HK)目标价至23.7港元评级“买入”",
                "features": {
                    "keywords": [
                        "汇丰",
                        "上海医药",
                        "目标价",
                        "买入"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【公司追踪】上海医药 (601607)丨收入增速回暖，利润有望反弹",
                "features": {
                    "keywords": [
                        "上海医药",
                        "收入增速",
                        "利润",
                        "反弹"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "继伦敦AIM和纳斯达克之后，李嘉诚投资的这家药企要再冲刺港交所！",
                "features": {
                    "keywords": [
                        "李嘉诚",
                        "药企",
                        "港交所",
                        "投资"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}